Corren J, Togias A, Bousquet J (eds.). Upper and Lower Respiratory Disease. New York, Basel: Marcel Dekker, Inc.; 2003. 552 p. Available at: https://www.aipro.info/wp/wp-content/uploads/2017/08/UPPER_LOWER_RESDPIRATORY.pdf.https://www.aipro.info/wp/wp-content/uploads/2017/08/UPPER_LOWER_RESDPIRATORY.pdf
Corren J, Togias A, Bousquet J (eds.). Upper and Lower Respiratory Disease. New York, Basel: Marcel Dekker, Inc.; 2003. 552 p. Available at: https://www.aipro.info/wp/wp-content/uploads/2017/08/UPPER_LOWER_RESDPIRATORY.pdf.https://www.aipro.info/wp/wp-content/uploads/2017/08/UPPER_LOWER_RESDPIRATORY.pdf
Giavina-Bianchi P, Aun MV, Takejima P, Kalil J, Agondi RC. United airway disease: current perspectives. J Asthma Allergy. 2016;9:93–100. https://doi.org/10.2147/jaa.s81541..
DOI: 10.2147/jaa.s81541
Samitas K, Carter A, Kariyawasam HH, Xanthou G. Upper and lower airway remodelling mechanisms in asthma, allergic rhinitis and chronic rhinosinusitis: The one airway concept revisited. Allergy. 2018;73(5):993–1002. https://doi.org/10.1111/all.13373..
DOI: 10.1111/all.13373
Eifan AO, Durham SR. Pathogenesis of rhinitis. Clin Exp Allergy. 2016;46(9):1139–1151. https://doi.org/10.1111/cea.12780..
DOI: 10.1111/cea.12780
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2) LEN and AllerGen). Allergy. 2008;63(Suppl. 86):8–160. https://doi.org/10.1111/j.1398-9995.2007.01620.x..
DOI: 10.1111/j.1398-9995.2007.01620.x
Ciprandi G, Caimmi D, Miraglia Del Giudice M, La Rosa M, Salpietro C, Marseglia GL. Recent developments in United airways disease. Allergy Asthma Immunol Res. 2012;4(4):171–177. https://doi.org/10.4168/aair.2012.4.4.171..
DOI: 10.4168/aair.2012.4.4.171
Bousquet J, Mantzouranis E, Cruz AA, Aït-Khaled N, Baena-Cagnani CE, Bleecker ER et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010;126(5):926–938. https://doi.org/10.1016/j.jaci.2010.07.019..
DOI: 10.1016/j.jaci.2010.07.019
Chuchalin AG, Khaltaev N, Antonov NS, Galkin DV, Manakov LG, Antonini P et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014;9:963–974. https://doi.org/10.2147/COPD.S67283..
DOI: 10.2147/COPD.S67283
Чучалин АГ, Геппе НА, Колосова НГ, Кондюрина ЕГ, Малахов АБ, Мизерницкий ЮЛ, Ревякина ВА. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». 5-е изд. М.: Оригинал-макет; 2017. 160 с. Режим доступа: http://astgmu.ru/wp-content/uploads/2018/10/Natsionalnaya-programma-BA-u-detej.-Strategiyalecheniya-i-profilaktika.pdf.http://astgmu.ru/wp-content/uploads/2018/10/Natsionalnaya-programma-BA-u-detej.-Strategiyalecheniya-i-profilaktika.pdf
Чучалин АГ, Геппе НА, Колосова НГ, Кондюрина ЕГ, Малахов АБ, Мизерницкий ЮЛ, Ревякина ВА. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». 5-е изд. М.: Оригинал-макет; 2017. 160 с. Режим доступа: http://astgmu.ru/wp-content/uploads/2018/10/Natsionalnaya-programma-BA-u-detej.-Strategiyalecheniya-i-profilaktika.pdf.http://astgmu.ru/wp-content/uploads/2018/10/Natsionalnaya-programma-BA-u-detej.-Strategiyalecheniya-i-profilaktika.pdf
Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958. https://doi.org/10.1016/j.jaci.2017.03.050..
DOI: 10.1016/j.jaci.2017.03.050
Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA et al. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108–352. https://doi.org/10.1002/alr.22073..
DOI: 10.1002/alr.22073
Ostovar A, Fokkens WJ, Vahdat K, Raeisi A, Mallahzadeh A, Farrokhi S. Epidemiology of chronic rhinosinusitis in Bushehr, southwestern region of Iran: a GA2LEN study. Rhinology. 2019;57(1):43–48. https://doi.org/10.4193/Rhin18.061..
DOI: 10.4193/Rhin18.061
Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24(5):758–764. https://doi.org/10.1183/09031936.04.00013904..
DOI: 10.1183/09031936.04.00013904
Хаитов МР, Намазова-Баранова ЛС, Ильина НИ, Курбачёва ОМ, Bachert C, Hellings PW и др. ARIA 2019: алгоритмы оказания помощи при аллергическом рините в России. Российский аллергологический журнал. 2020;17(1):7–22. https://doi.org/110.36691/RAJ.2020.17.1.001..
DOI: 110.36691/RAJ.2020.17.1.001
Астафьева НГ, Баранов АА, Вишнева ЕА, Дайхес НА, Жестков АВ, Ильина НИ и др. Аллергический ринит: клинические рекомендации. М.; 2020. 70 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/261_1.https://cr.minzdrav.gov.ru/recomend/261_1
Астафьева НГ, Баранов АА, Вишнева ЕА, Дайхес НА, Жестков АВ, Ильина НИ и др. Аллергический ринит: клинические рекомендации. М.; 2020. 70 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/261_1.https://cr.minzdrav.gov.ru/recomend/261_1
Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–948. https://doi.org/10.1111/j.1398-9995.2007.01451.x..
DOI: 10.1111/j.1398-9995.2007.01451.x
Tohidinik HR, Mallah N, Takkouche B. History of allergic rhinitis and risk of asthma; a systematic review and meta-analysis. World Allergy Organ J. 2019;12(10):100069. https://doi.org/10.1016/j.waojou.2019.100069..
DOI: 10.1016/j.waojou.2019.100069
Bousquet J, Bachert C, Canonica GW, Casale TB, Cruz AA, Lockey RJ, Zuberbier T. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol. 2009;124(3):428–433. https://doi.org/10.1016/j.jaci.2009.06.027..
DOI: 10.1016/j.jaci.2009.06.027
Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J, Bockelbrink A et al. Chronic rhinosinusitis in Europe – an underestimated disease. A GA²LEN study. Allergy. 2011;66(9):1216–1223. https://doi.org/10.1111/j.1398-9995.2011.02646.x..
DOI: 10.1111/j.1398-9995.2011.02646.x
Hirsch AG, Stewart WF, Sundaresan AS, Young AJ, Kennedy TL, Scott Greene J et al. Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample. Allergy. 2017;72(2):274–281. https://doi.org/10.1111/all.13042..
DOI: 10.1111/all.13042
Shi JB, Fu QL, Zhang H, Cheng L, Wang YJ, Zhu DD et al. Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities. Allergy. 2015;70(5):533–539. https://doi.org/10.1111/all.12577..
DOI: 10.1111/all.12577
Pilan RR, Pinna FR, Bezerra TF, Mori RL, Padua FG, Bento RF et al. Prevalence of chronic rhinosinusitis in Sao Paulo. Rhinology. 2012;50(2):129–138. https://doi.org/10.4193/Rhino11.256..
DOI: 10.4193/Rhino11.256
Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl. 29):1–464. https://doi.org/10.4193/Rhin20.600..
DOI: 10.4193/Rhin20.600
Philpott CM, Erskine S, Hopkins C, Kumar N, Anari S, Kara N et al. Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. Respir Res. 2018;19(1):129. https://doi.org/10.1186/s12931-018-0823-y..
DOI: 10.1186/s12931-018-0823-y
Khan A, Vandeplas G, Huynh TMT, Joish VN, Mannent L, Tomassen P et al. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57(1):32–42. https://doi.org/10.4193/Rhin17.255..
DOI: 10.4193/Rhin17.255
Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449–1456.e4. https://doi.org/10.1016/j.jaci.2015.12.1324..
DOI: 10.1016/j.jaci.2015.12.1324
Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45–53. https://doi.org/10.2147/JAA.S86251..
DOI: 10.2147/JAA.S86251
Lin DC, Chandra RK, Tan BK, Zirkle W, Conley DB, Grammer LC et al. Association between severity of asthma and degree of chronic rhinosinusitis. Am J Rhinol Allergy. 2011;25(4):205–208. https://doi.org/10.2500/ajra.2011.25.3613..
DOI: 10.2500/ajra.2011.25.3613
Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308–1321. https://doi.org/10.1183/13993003.00779-2015..
DOI: 10.1183/13993003.00779-2015
Promsopa C, Kansara S, Citardi MJ, Fakhri S, Porter P, Luong A. Prevalence of confirmed asthma varies in chronic rhinosinusitis subtypes. Int Forum Allergy Rhinol. 2016;6(4):373–377. https://doi.org/10.1002/alr.21674..
DOI: 10.1002/alr.21674
Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716–725. https://doi.org/10.1038/nm.2678..
DOI: 10.1038/nm.2678
Agache I. Severe asthma phenotypes and endotypes. Semin Immunol. 2019;46:101301. https://doi.org/10.1016/j.smim.2019.101301..
DOI: 10.1016/j.smim.2019.101301
Damask CC, Ryan MW, Casale TB, Castro M, Franzese CB, Lee SE et al. Targeted Molecular Therapies in Allergy and Rhinology. Otolaryngol Head Neck Surg. 2021;164(Suppl. 1):S1–S21. https://doi.org/10.1177/0194599820965233..
DOI: 10.1177/0194599820965233
Bagnasco D, Testino E, Nicola S, Melissari L, Russo M, Canevari RF et al. Specific Therapy for T2 Asthma. J Pers Med. 2022;12(4):593. https://doi.org/10.3390/jpm12040593..
DOI: 10.3390/jpm12040593
Karta MR, Broide DH, Doherty TA. Insights into Group 2 Innate Lymphoid Cells in Human Airway Disease. Curr Allergy Asthma Rep. 2016;16(1):8. https://doi.org/10.1007/s11882-015-0581-6..
DOI: 10.1007/s11882-015-0581-6
Sugita K, Steer CA, Martinez-Gonzalez I, Altunbulakli C, Morita H, CastroGiner F et al. Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients. J Allergy Clin Immunol. 2018;141(1):300–310.e11. https://doi.org/10.1016/j.jaci.2017.02.038..
DOI: 10.1016/j.jaci.2017.02.038
Smith SG, Chen R, Kjarsgaard M, Huang C, Oliveria JP, O’Byrne PM et al. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J Allergy Clin Immunol. 2016;137(1):75–86.e8. https://doi.org/10.1016/j.jaci.2015.05.037..
DOI: 10.1016/j.jaci.2015.05.037
Halim TY, Steer CA, Mathä L, Gold MJ, Martinez-Gonzalez I, McNagny KM et al. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity. 2014;40(3):425–435. https://doi.org/10.1016/j.immuni.2014.01.011..
DOI: 10.1016/j.immuni.2014.01.011
Oliphant CJ, Hwang YY, Walker JA, Salimi M, Wong SH, Brewer JM et al. MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion. Immunity. 2014;41(2):283–295. https://doi.org/10.1016/j.immuni.2014.06.016..
DOI: 10.1016/j.immuni.2014.06.016
Nordengrün M, Michalik S, Völker U, Bröker BM, Gómez-Gascón L. The quest for bacterial allergens. Int J Med Microbiol. 2018;308(6):738–750. https://doi.org/10.1016/j.ijmm.2018.04.003..
DOI: 10.1016/j.ijmm.2018.04.003
Schmidt F, Meyer T, Sundaramoorthy N, Michalik S, Surmann K, Depke M et al. Characterization of human and Staphylococcus aureus proteins in respiratory mucosa by in vivo- and immunoproteomics. J Proteomics. 2017;155:31–39. https://doi.org/10.1016/j.jprot.2017.01.008..
DOI: 10.1016/j.jprot.2017.01.008
Van Zele T, Gevaert P, Watelet JB, Claeys G, Holtappels G, Claeys C et al. Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. J Allergy Clin Immunol. 2004;114(4):981–983. https://doi.org/10.1016/j.jaci.2004.07.013..
DOI: 10.1016/j.jaci.2004.07.013
Verbruggen K, Van Cauwenberge P, Bachert C. Anti-IgE for the treatment of allergic rhinitis – and eventually nasal polyps? Int Arch Allergy Immunol. 2009;148(2):87–98. https://doi.org/10.1159/000155739..
DOI: 10.1159/000155739
Akdis CA, Bachert C, Cingi C, Dykewicz MS, Hellings PW, Naclerio RM et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2013;131(6):1479–1490. https://doi.org/10.1016/j.jaci.2013.02.036..
DOI: 10.1016/j.jaci.2013.02.036
Backman H, Räisänen P, Hedman L, Stridsman C, Andersson M, Lindberg A et al. Increased prevalence of allergic asthma from 1996 to 2006 and further to 2016-results from three population surveys. Clin Exp Allergy. 2017;47(11):1426–1435. https://doi.org/10.1111/cea.12963..
DOI: 10.1111/cea.12963
Mansur AH, Srivastava S, Mitchell V, Sullivan J, Kasujee I. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety. Respir Med. 2017;124:36–43. https://doi.org/10.1016/j.rmed.2017.01.008..
DOI: 10.1016/j.rmed.2017.01.008
Boushey HA Jr. Experiences with monoclonal antibody therapy for allergic asthma. J Allergy Clin Immunol. 2001;108(Suppl. 2):S77–83.https://doi.org/10.1067/mai.2001.116434..
DOI: 10.1067/mai.2001.116434
Kopp MV. Omalizumab: Anti-IgE therapy in allergy. Curr Allergy Asthma Rep. 2011;11(2):101–106. https://doi.org/10.1007/s11882-010-0173-4..
DOI: 10.1007/s11882-010-0173-4
Johansson SG, Haahtela T, O’Byrne PM. Omalizumab and the immune system: an overview of preclinical and clinical data. Ann Allergy Asthma Immunol. 2002;89(2):132–138. https://doi.org/10.1016/S1081-1206(10)61928-X..
DOI: 10.1016/S1081-1206(10)61928-X
Sutton BJ, Gould HJ. The human IgE network. Nature. 1993;366(6454): 421–428. https://doi.org/10.1038/366421a0..
DOI: 10.1038/366421a0
Heusser C, Jardieu P. Therapeutic potential of anti-IgE antibodies. Curr Opin Immunol. 1997;9(6):805–813. https://doi.org/10.1016/s0952-7915(97)80182-3..
DOI: 10.1016/s0952-7915(97)80182-3
Davies AM, Allan EG, Keeble AH, Delgado J, Cossins BP, Mitropoulou AN et al. Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab. J Biol Chem. 2017;292(24):9975–9987. https://doi.org/10.1074/jbc.M117.776476..
DOI: 10.1074/jbc.M117.776476
Емельянов АВ, Ильина НИ, Карнеева ОВ, Карпищенко СА, Ким ИА, Курбачева ОМ и др. Нерешенные вопросы ведения пациентов с тяжелым аллергическим ринитом и полипозным риносинуситом. Возможности анти-IgE терапии. Российская оториноларингология. 2020;19(3):88–99. https://doi.org/10.18692/1810-4800-2020-3-88-99..
DOI: 10.18692/1810-4800-2020-3-88-99
Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–316.https://doi.org/10.1111/j.1398-9995.2004.00772.x..
DOI: 10.1111/j.1398-9995.2004.00772.x
Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011;66(5):671–678. https://doi.org/10.1111/j.1398-9995.2010.02522.x..
DOI: 10.1111/j.1398-9995.2010.02522.x
Ohta K, Miyamoto T, Amagasaki T, Yamamoto M. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. Respirology. 2009;14(8):1156–1165. https://doi.org/10.1111/j.1440-1843.2009.01633.x..
DOI: 10.1111/j.1440-1843.2009.01633.x
Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy. 2004;59(7):701–708. https://doi.org/10.1111/j.1398-9995.2004.00533.x..
DOI: 10.1111/j.1398-9995.2004.00533.x
Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34(4):632–638. https://doi.org/10.1111/j.1365-2222.2004.1916.x..
DOI: 10.1111/j.1365-2222.2004.1916.x
Buhl R, Solèr M, Matz J, Townley R, O’Brien J, Noga O et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J. 2002;20(1):73–78. https://doi.org/10.1183/09031936.02.00278102..
DOI: 10.1183/09031936.02.00278102
Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184–190. https://doi.org/10.1067/mai.2001.117880..
DOI: 10.1067/mai.2001.117880
Solèr M, Matz J, Townley R, Buhl R, O’Brien J, Fox H et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254–261. https://doi.org/10.1183/09031936.01.00092101..
DOI: 10.1183/09031936.01.00092101
Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol. 2003;111(1):87–90. https://doi.org/10.1067/mai.2003.49..
DOI: 10.1067/mai.2003.49
Finn A, Gross G, van Bavel J, Lee T, Windom H, Everhard F et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol. 2003;111(2):278–284. https://doi.org/10.1067/mai.2003.54..
DOI: 10.1067/mai.2003.54
Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108(2):E36. https://doi.org/10.1542/peds.108.2.e36..
DOI: 10.1542/peds.108.2.e36
Grimaldi-Bensouda L, Zureik M, Aubier M, Humbert M, Levy J, Benichou J et al. Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma. Chest. 2013;143(2):398–405. https://doi.org/10.1378/chest.12-1372..
DOI: 10.1378/chest.12-1372
Eisner MD, Zazzali JL, Miller MK, Bradley MS, Schatz M. Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study. J Asthma. 2012;49(6):642–648. https://doi.org/10.3109/02770903.2012.690477..
DOI: 10.3109/02770903.2012.690477
Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134(3):560–567.e4. https://doi.org/10.1016/j.jaci.2014.02.007..
DOI: 10.1016/j.jaci.2014.02.007
Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med. 2009;103(11):1725–1731. https://doi.org/10.1016/j.rmed.2009.05.002..
DOI: 10.1016/j.rmed.2009.05.002
Cazzola M, Camiciottoli G, Bonavia M, Gulotta C, Ravazzi A, Alessandrini A et al. Italian real-life experience of omalizumab. Respir Med. 2010;104(10):1410–1416. https://doi.org/10.1016/j.rmed.2010.04.013..
DOI: 10.1016/j.rmed.2010.04.013
Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A et al. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med. 2009;103(11):1633–1642. https://doi.org/10.1016/j.rmed.2009.06.014..
DOI: 10.1016/j.rmed.2009.06.014
Barnes N, Menzies-Gow A, Mansur AH, Spencer D, Percival F, Radwan A, Niven R. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma. 2013;50(5):529–536. https://doi.org/10.3109/02770903.2013.790419..
DOI: 10.3109/02770903.2013.790419
Schumann C, Kropf C, Wibmer T, Rüdiger S, Stoiber KM, Thielen A et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J. 2012;6(4):215–227. https://doi.org/10.1111/j.1752-699X.2011.00263.x..
DOI: 10.1111/j.1752-699X.2011.00263.x
Vennera Mdel C, Pérez De Llano L, Bardagí S, Ausin P, Sanjuas C, González H et al. Omalizumab therapy in severe asthma: experience from the Spanish registry – some new approaches. J Asthma. 2012;49(4):416–422. https://doi.org/10.3109/02770903.2012.668255..
DOI: 10.3109/02770903.2012.668255
Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107(8):1141–1151. https://doi.org/10.1016/j.rmed.2013.04.017..
DOI: 10.1016/j.rmed.2013.04.017
Sposato B, Scalese M, Latorre M, Scichilone N, Matucci A, Milanese M et al. Effects of omalizumab in severe asthmatics across ages: A real life Italian experience. Respir Med. 2016;119:141–149. https://doi.org/10.1016/j.rmed.2016.09.005..
DOI: 10.1016/j.rmed.2016.09.005
Bhutani M, Yang WH, Hébert J, de Takacsy F, Stril JL. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study. PLoS ONE. 2017;12(8):e0183869. https://doi.org/10.1371/journal.pone.0183869..
DOI: 10.1371/journal.pone.0183869
Lee JH, Lee HY, Jung CG, Ban GY, Shin YS, Ye YM et al. Therapeutic Effect of Omalizumab in Severe Asthma: A Real-World Study in Korea. Allergy Asthma Immunol Res. 2018;10(2):121–130. https://doi.org/10.4168/aair.2018.10.2.121..
DOI: 10.4168/aair.2018.10.2.121
Pilon D, Kavati A, Ortiz B, Paknis B, Vegesna A, Schiffman B et al. Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma. Allergy Asthma Proc. 2018;39(2):127–135. https://doi.org/10.2500/aap.2018.39.4111..
DOI: 10.2500/aap.2018.39.4111
Papaioannou AI, Mplizou M, Porpodis K, Fouka E, Zervas E, Samitas K et al. Long-term efficacy and safety of omalizumab in patients with allergic asthma: A real-life study. Allergy Asthma Proc. 2021;42(3):235–242. https://doi.org/10.2500/aap.2021.42.210014..
DOI: 10.2500/aap.2021.42.210014
Torres-Duque CA, Ocampo-Gómez J, Castillo MM, Cano-Rosales D, Giraldo-Montoya Á, Rodríguez F et al. Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia. BMC Pulm Med. 2022;22(1):447. https://doi.org/10.1186/s12890-022-02246-x..
DOI: 10.1186/s12890-022-02246-x
Su N, Zhi L, Liu F, Wang Y, Zhang Q, Liu X et al. Real-World Safety and Effectiveness of Omalizumab in Moderate to Severe Allergic Asthma Patients in China: A Post-Authorization Study. J Asthma Allergy. 2023;16:625–636. https://doi.org/10.2147/JAA.S406628..
DOI: 10.2147/JAA.S406628
Bousquet J, Brusselle G, Buhl R, Busse WW, Cruz AA, Djukanovic R et al. Care pathways for the selection of a biologic in severe asthma. Eur Respir J. 2017;50(6):1701782. https://doi.org/10.1183/13993003.01782-2017..
DOI: 10.1183/13993003.01782-2017
Alhossan A, Lee CS, MacDonald K, Abraham I. “Real-life” Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. J Allergy Clin Immunol Pract. 2017;5(5):1362–1370.e2. https://doi.org/10.1016/j.jaip.2017.02.002..
DOI: 10.1016/j.jaip.2017.02.002
Menzella F, Galeone C, Formisano D, Castagnetti C, Ruggiero P, Simonazzi A, Zucchi L. Real-life Efficacy of Omalizumab After 9 Years of Follow-up. Allergy Asthma Immunol Res. 2017;9(4):368–372. https://doi.org/10.4168/aair.2017.9.4.368..
DOI: 10.4168/aair.2017.9.4.368
Faulkner KM, MacDonald K, Abraham I, Alhossan A, Lee CS. “Real-world” effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis. Expert Rev Clin Immunol. 2021;17(1):73–83. https://doi.org/10.1080/1744666X.2020.1856658..
DOI: 10.1080/1744666X.2020.1856658
MacDonald KM, Kavati A, Ortiz B, Alhossan A, Lee CS, Abraham I. Shortand long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008–2018. Expert Rev Clin Immunol. 2019;15(5):553–569. https://doi.org/10.1080/1744666X.2019.1574571..
DOI: 10.1080/1744666X.2019.1574571
Bousquet J, Humbert M, Gibson PG, Kostikas K, Jaumont X, Pfister P, Nissen F. Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies. J Allergy Clin Immunol Pract. 2021;9(7):2702–2714. https://doi.org/10.1016/j.jaip.2021.01.011..
DOI: 10.1016/j.jaip.2021.01.011
Hanania NA, Niven R, Chanez P, Antoine D, Pfister P, Garcia Conde L, Jaumont X. Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma. World Allergy Organ J. 2022;15(10):100695. https://doi.org/10.1016/j.waojou.2022.100695..
DOI: 10.1016/j.waojou.2022.100695
Pfaar O, Gehrt F, Li H, Rudhart SA, Nastev A, Stuck BA, Hoch S. Anti-IgE: A treatment option in allergic rhinitis? Allergol Select. 2021;5:119–127. https://doi.org/10.5414/ALX02205E..
DOI: 10.5414/ALX02205E
Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR et al. Use of an anti-IgE humanized monoclonal antibody in ragweedinduced allergic rhinitis. J Allergy Clin Immunol. 1997;100(1):110–121. https://doi.org/10.1016/s0091-6749(97)70202-1..
DOI: 10.1016/s0091-6749(97)70202-1
Racine-Poon A, Botta L, Chang TW, Davis FM, Gygax D, Liou RS et al. Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis. Clin Pharmacol Ther. 1997;62(6):675–690. https://doi.org/10.1016/S0009-9236(97)90087-4..
DOI: 10.1016/S0009-9236(97)90087-4
Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91(2):160–167. https://doi.org/10.1016/S1081-1206(10)62171-0..
DOI: 10.1016/S1081-1206(10)62171-0
Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009;39(2):271–279. https://doi.org/10.1111/j.1365-2222.2008.03121.x..
DOI: 10.1111/j.1365-2222.2008.03121.x
Okubo K, Ogino S, Nagakura T, Ishikawa T. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int. 2006;55(4):379–386. https://doi.org/10.2332/allergolint.55.379..
DOI: 10.2332/allergolint.55.379
Ogino S, Nagakura T, Okubo K, Sato N, Takahashi M, Ishikawa T. Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated. Int Arch Allergy Immunol. 2009;149(3):239–245. https://doi.org/10.1159/000199719..
DOI: 10.1159/000199719
Okubo K, Okano M, Sato N, Tamaki Y, Suzuki H, Uddin A, Fogel R. Add-On Omalizumab for Inadequately Controlled Severe Pollinosis Despite Standard-of-Care: A Randomized Study. J Allergy Clin Immunol Pract. 2020;8(9):3130–3140.e2. https://doi.org/10.1016/j.jaip.2020.04.068..
DOI: 10.1016/j.jaip.2020.04.068
Tsabouri S, Tseretopoulou X, Priftis K, Ntzani EE. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract. 2014;2(3):332–340.e1. https://doi.org/10.1016/j.jaip.2014.02.001..
DOI: 10.1016/j.jaip.2014.02.001
Tsabouri S, Ntritsos G, Koskeridis F, Evangelou E, Olsson P, Kostikas K. Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis. Rhinology. 2021;59(6):501–510. https://doi.org/10.4193/Rhin21.159..
DOI: 10.4193/Rhin21.159
Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59(7):709–717. https://doi.org/10.1111/j.1398-9995.2004.00550.x..
DOI: 10.1111/j.1398-9995.2004.00550.x
Bachert C, Gevaert E. Advances in rhinitis and rhinosinusitis in 2015. J Allergy Clin Immunol. 2016;138(5):1277–1283. https://doi.org/10.1016/j.jaci.2016.09.008..
DOI: 10.1016/j.jaci.2016.09.008
Erskine S, Hopkins C, Kumar N, Wilson J, Clark A, Robertson A et al. A cross sectional analysis of a case-control study about quality of life in CRS in the UK; a comparison between CRS subtypes. Rhinology. 2016;54(4):311–315. https://doi.org/10.4193/Rhino15.361..
DOI: 10.4193/Rhino15.361
Hoehle LP, Phillips KM, Bergmark RW, Caradonna DS, Gray ST, Sedaghat AR. Symptoms of chronic rhinosinusitis differentially impact general healthrelated quality of life. Rhinology. 2016;54(4):316–322. https://doi.org/10.4193/Rhino16.211..
DOI: 10.4193/Rhino16.211
Naclerio R, Lockey R. Sinonasal Disease: An Underappreciated Entity. J Allergy Clin Immunol Pract. 2020;8(5):1567–1568. https://doi.org/10.1016/j.jaip.2020.01.064..
DOI: 10.1016/j.jaip.2020.01.064
De Schryver E, Devuyst L, Derycke L, Dullaers M, Van Zele T, Bachert C, Gevaert P. Local immunoglobulin e in the nasal mucosa: clinical implications. Allergy Asthma Immunol Res. 2015;7(4):321–331. https://doi.org/10.4168/aair.2015.7.4.321..
DOI: 10.4168/aair.2015.7.4.321
Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110–116.e1. https://doi.org/10.1016/j.jaci.2012.07.047..
DOI: 10.1016/j.jaci.2012.07.047
Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595–605. https://doi.org/10.1016/j.jaci.2020.05.032..
DOI: 10.1016/j.jaci.2020.05.032
Gevaert P, Saenz R, Corren J, Han JK, Mullol J, Lee SE et al. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. J Allergy Clin Immunol. 2022;149(3):957–965.e3. https://doi.org/10.1016/j.jaci.2021.07.045..
DOI: 10.1016/j.jaci.2021.07.045
Barroso B, Valverde-Monge M, Alobid I, Olaguibel JM, Rial MJ, Quirce S et al. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti-IL-5 Biologics: A Real-Life Study. J Investig Allergol Clin Immunol. 2023;33(1):37–44. https://doi.org/10.18176/jiaci.0812..
DOI: 10.18176/jiaci.0812
Agache I, Rocha C, Beltran J, Song Y, Posso M, Solà I et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1043–1057. https://doi.org/10.1111/all.14235..
DOI: 10.1111/all.14235
Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol. 2003;91(2):154–159. https://doi.org/10.1016/S1081-1206(10)62170-9..
DOI: 10.1016/S1081-1206(10)62170-9
Bardelas J, Figliomeni M, Kianifard F, Meng X. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma. 2012;49(2):144–152. https://doi.org/10.3109/02770903.2011.648296..
DOI: 10.3109/02770903.2011.648296
Cruz AA, Lima F, Sarinho E, Ayre G, Martin C, Fox H, Cooper PJ. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy. 2007;37(2):197–207. https://doi.org/10.1111/j.1365-2222.2007.02650.x..
DOI: 10.1111/j.1365-2222.2007.02650.x
Cox L, Lieberman P, Wallace D, Simons FE, Finegold I, Platts-Mills T, Schwartz L. American Academy of Allergy, Asthma & Immunology/ American College of Allergy, Asthma & Immunology OmalizumabAssociated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol. 2011;128(1):210–212. https://doi.org/10.1016/j.jaci.2011.04.010..
DOI: 10.1016/j.jaci.2011.04.010
Lieberman PL, Umetsu DT, Carrigan GJ, Rahmaoui A. Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study. J Allergy Clin Immunol. 2016;138(3):913–915.e2. https://doi.org/10.1016/j.jaci.2016.03.030..
DOI: 10.1016/j.jaci.2016.03.030
Metz M, Vadasz Z, Kocatürk E, Giménez-Arnau AM. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence. Clin Rev Allergy Immunol. 2020;59(1):38–45. https://doi.org/10.1007/s12016-020-08794-6..
DOI: 10.1007/s12016-020-08794-6